Literatura académica sobre el tema "Antimalaria- Drug"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Antimalaria- Drug".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Antimalaria- Drug"
Yousif, M. A. y A. A. Adeel. "Antimalarials prescribing patterns in Gezira state: precepts and practices". Eastern Mediterranean Health Journal 6, n.º 5-6 (15 de diciembre de 2000): 939–47. http://dx.doi.org/10.26719/2000.6.5-6.939.
Texto completoUjuamala Uloma Ezeani, Penaere Theresa Osahon y Michael Chukwudi Ezeani. "Pattern of anti-malarial drugs and artemether combination therapy adherence in an institution based medical centre, Nigeria". World Journal of Advanced Research and Reviews 8, n.º 3 (30 de diciembre de 2020): 162–70. http://dx.doi.org/10.30574/wjarr.2020.8.3.0437.
Texto completoKocisko, David A. y Byron Caughey. "Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo". Journal of Virology 80, n.º 2 (15 de enero de 2006): 1044–46. http://dx.doi.org/10.1128/jvi.80.2.1044-1046.2006.
Texto completoGil, JP y E. Gil Berglund. "CYP2C8 and antimalaria drug efficacy". Pharmacogenomics 8, n.º 2 (febrero de 2007): 187–98. http://dx.doi.org/10.2217/14622416.8.2.187.
Texto completoHede, K. "Antimalaria Drug Offers Antitumor Strategies". JNCI Journal of the National Cancer Institute 103, n.º 20 (4 de octubre de 2011): 1490–91. http://dx.doi.org/10.1093/jnci/djr423.
Texto completoBradbury, Jane. "Synthetic antimalaria drug enters clinical trials". Lancet Infectious Diseases 4, n.º 10 (octubre de 2004): 598. http://dx.doi.org/10.1016/s1473-3099(04)01161-2.
Texto completoLinda Ekawati, Linda Ekawati, Beta Achromi Nurohmah Beta Achromi Nurohmah, Jufrizal Syahri Jufrizal Syahri y Bambang Purwono Bambang Purwono. "Substituted 3-styryl-2-pyrazoline Derivatives as an Antimalaria: Synthesis, in vitro Assay, Molecular Docking, Druglikeness Analysis and Admet Prediction". Sains Malaysiana 51, n.º 10 (31 de octubre de 2022): 3215–36. http://dx.doi.org/10.17576/jsm-2022-5110-09.
Texto completoPeter, Sijongesonke y Blessing Atim Aderibigbe. "Ferrocene-Based Compounds with Antimalaria/Anticancer Activity". Molecules 24, n.º 19 (7 de octubre de 2019): 3604. http://dx.doi.org/10.3390/molecules24193604.
Texto completoMuhaimin, Muhaimin, Yusnaidar Yusnaidar y Hilda Amanda. "Antimalaria Activity of Macaranga Gigantea Leaves Extracts". Journal of The Indonesian Society of Integrated Chemistry 10, n.º 2 (6 de abril de 2019): 23–32. http://dx.doi.org/10.22437/jisic.v10i2.6581.
Texto completoTahir, Iqmal, Mudasir Mudasir, Irza Yulistia y Mustofa Mustofa. "QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS (QSAR) OF VINCADIFFORMINE ANALOGUES AS THE ANTIPLASMODIAL COMPOUNDS OF THE CHLOROQUINOSENSIBLE STRAIN". Indonesian Journal of Chemistry 5, n.º 3 (15 de junio de 2010): 255–60. http://dx.doi.org/10.22146/ijc.21800.
Texto completoTesis sobre el tema "Antimalaria- Drug"
Kumar, Hirdesh. "Identification of vaccine and drug targets against malaria". Thesis, IIT Delhi, 2016. http://localhost:8080/xmlui/handle/12345678/7008.
Texto completoPongtavornpinyo, Wirichada. "Mathematical modelling of antimalarial drug resistance". Thesis, University of Liverpool, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.428249.
Texto completoMatthews, H. "Accelerating antimalarial drug discovery through repositioning". Thesis, University of Salford, 2013. http://usir.salford.ac.uk/36885/.
Texto completoSumanadasa, Subathdrage Dulangi Madushika. "Investigation of Novel Antimalarial Agents and Novel Target Identification Approaches". Thesis, Griffith University, 2015. http://hdl.handle.net/10072/367036.
Texto completoThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Biomolecular and Physical Sciences
Science, Environment, Engineering and Technology
Full Text
Uhlemann, Anne-Catrin. "Plasmodium falciparum transporters as antimalarial drug targets". Thesis, St George's, University of London, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.559278.
Texto completoPrice, K. E. "Antimalarial drug discovery : exploring the MEP pathway". Thesis, University of Liverpool, 2016. http://livrepository.liverpool.ac.uk/3005814/.
Texto completoSilal, Sheetal Prakash. "A simulation model of antimalarial drug resistance". Master's thesis, University of Cape Town, 2009. http://hdl.handle.net/11427/9003.
Texto completoMalaria ranks among the world's most important tropical parasitic diseases with world prevalence figures between 350 and 550 million clinical cases per annum. [WHO, 2008a] 'Treatment and prevention of malaria places a considerable burden on struggling economies where the disease is rampant. Research in malaria does not stop as the change in response to antimalarial drug treatment requires the development of new drugs and innovation in the use of old drugs. This thesis focused on building a model of the spread of resistance to Sulfadoxine/Pyrimethamine (SP) in a setting where both SP and SP in artemisinin-based combination therapy (ACT) are the first line therapies for malaria. The model itself is suitable to any low transmission setting where antimalarial drug resistance exists but the country of choice in this modeling exercise was Mozambique. The model was calibrated using parameters specific to the malaria situation in Mozambique. This model was intended to be used to aid decision making in countries where antimalarial drug resistance exists to help prevent resistance spreading to such an extent that drugs lose their usefulness in curing malaria. The modeling technique of choice was differential equation modeling; a simulation technique that falls under the System Dynamics banner in the Operations Research armamentarium. It is a technique that allowed the modeling of stocks and flows that represent different stages or groupings in the disease process and the rate of movement between these stages respectively. The base model that was built allowed infected individuals to become infectious, to be treated with SP or ACT and to be sensitive to or fail treatment. Individuals were allowed a period of temporary immunity where they would not be reinfected until the residual SP had been eliminated from their bloodstream. The base model was then further developed to include the pharmacokinetic properties of SP where individuals were allowed to be reinfected with certain strains of infection given the level of residual drug in their bloodstream after their current infection had been cleared. The models used in this thesis were built with idea of expanding on previous models and using available data to improve parameter estimates. The model at its core is similar to the resistance model used in Koella and Antia [2003] where differential equation modeling was used to monitor a population as it became infected with a sensitive or resistant infection and then University of Cape Town recovered. The inclusion in the model of the PK component was derived from Prudhomme-O'Meara et al. [2006] where individuals could be reinfected depending on the residual drug in their bloodstream. Rather than modeling simply sensitive and resistant infections, mutations categories were used as was the case in Watkins et al. [2005] population genetics model. The use of mutation categories allowed one to use parameters specific to these categories rather than the sensitive/resistant stratification and this is particularly relevant in Mozambique where all mutation categories still exhibit some degree of sensitivity to treatment i.e. total resistance has not yet developed for any particular mutation category. The last adaptation of the model was to use gametocyte information directly to determine human infectiousness rather than through using a gametocyte switching rate (constant multiplier used to convert parasite density to gametocyte density) as was done in Pongtavompinyo [2006]. The models developed in this thesis found that the existing vector control and drug policy in Mozambique had the major effect of decreasing total prevalence of malaria by approximately 70% in the 11 year period. The distribution of Res3 (presence of DHFR triple) and Res5 (presence of DHFR triple and DHPS double) infections changed over the 11 year period with Res3 infections initially increasing and then decreasing while Res5 infections started low and increased to overtake Res3 infections. The timing of the change in this composition of infection corresponds with the introduction of ACT and thus it appears that the use of ACT prompted the increased prevalence of quintuple parasites over DHFR triple and sensitive parasites. The total number of failures decreased substantially after the introduction of ACT to 17% of its previous level. The results of the base model corresponded with the observed data from the SEACAT study in terms of the magnitude and the trends of the impact of the change to ACT policy, but underestimated the impact of the vector control strategies compared to rapid effect noted in Sharp et al. [2007]. The Scenario testing of the base model showed that vector control is an effective strategy to reduce prevalence and that it is sensitive to the time at which the control is started as it decreased prevalence very gradually. The Scenario testing of the base model also showed that the introduction of ACT in Mozambique had a greater impact on reducing prevalence and that the start time of the ACT strategy did not decrease the effect on prevalence though earlier start times decreased the total number of resistance cases. The ratio of Res5 to Res3 infections increased faster when ACT was the treatment policy than when SP was the policy. Thus higher values of this ratio are associated with ACT being the treatment strategy in place. Thus differential equation modeling is an effective modeling tool to capture the spread of disease and to test the effects of policy interventions as it allows one to assess these effects on populations and averages out individual-level intricacies to better inform policy decisions.
Kay, Katherine. "Pharmacological modelling to investigate antimalarial drug treatment". Thesis, University of Liverpool, 2013. http://livrepository.liverpool.ac.uk/12413/.
Texto completoAl, Helal Mohammad Abdullah. "Pharmacodynamics of antimalarial endoperoxide drugs". Thesis, University of Liverpool, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.526822.
Texto completoBlake, Lynn Dong. "Antimalarial Exoerythrocytic Stage Drug Discovery and Resistance Studies". Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6182.
Texto completoLibros sobre el tema "Antimalaria- Drug"
Silikas, Nikolaos. Rational drug design of protoberberine antimalarials. Manchester: University of Manchester, 1995.
Buscar texto completoCsizmadia, Emanuel. Antimalarial drugs: Costs, safety and efficacy. New York: Nova Biomedical Books, 2009.
Buscar texto completoEmanuel, Csizmadia y Kalnoky Istvan, eds. Antimalarial drugs: Costs, safety, and efficacy. Hauppauge, NY: Nova Science, 2009.
Buscar texto completoLi, Qigui. Antimalarial drugs: Age of the artemisinins. Hauppauge, N.Y: Nova Science, 2010.
Buscar texto completoM, Gomes, Pang L y World Health Organization, eds. Interventions to improve antimalarial use. Geneva: World Health Organization, 1998.
Buscar texto completoOrganization, World Health, ed. A Practical handbook on the pharmacovigilance of antimalarial medicines. Geneva, Switzerland: World Health Organization, 2008.
Buscar texto completoKiang, Tony K. L., Kyle John Wilby y Mary H. H. Ensom. Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-10527-7.
Texto completoStaines, Henry M. Treatment and Prevention of Malaria: Antimalarial Drug Chemistry, Action and Use. Basel: Springer Basel, 2012.
Buscar texto completoPeters, Wallace. Chemotherapy and drug resistance in malaria. 2a ed. London: Academic Press, 1987.
Buscar texto completoCentral Council for Research in Unani Medicine (India), ed. Potential antimalarial herbal drugs from South Eastern India: Bihar and Orissa states. New Delhi: Central Council for Research in Unani Medicine, Ministry of Health & Family Welfare, Govt. of India, 2000.
Buscar texto completoCapítulos de libros sobre el tema "Antimalaria- Drug"
Adedeji, Waheed A., Tunde Balogun, Fatai A. Fehintola y Gene D. Morse. "Drug-Drug Interactions of Antimalarial Drugs". En Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions, 503–14. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-72416-4_12.
Texto completoShah, Naman K. y Neena Valecha. "Antimalarial drug resistance". En Advances in Malaria Research, 383–407. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2016. http://dx.doi.org/10.1002/9781118493816.ch14.
Texto completoKiang, Tony K. L., Kyle John Wilby y Mary H. H. Ensom. "Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials". En Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials, 17–25. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_3.
Texto completoPile, Kevin D., Garry G. Graham, Constance H. Katelaris y Richard O. Day. "Antimalarial Drugs". En Compendium of Inflammatory Diseases, 97–101. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_9.
Texto completoPile, Kevin, Garry G. Graham, Constance H. Katelaris y Richard O. Day. "Antimalarial Drugs". En Encyclopedia of Inflammatory Diseases, 1–6. Basel: Springer Basel, 2013. http://dx.doi.org/10.1007/978-3-0348-0620-6_9-1.
Texto completoParikh, Sunil, Ming-Na Tina Lee y Francesca T. Aweeka. "Antimalarial Agents". En Drug Interactions in Infectious Diseases, 561–79. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-213-7_16.
Texto completoTull, Thomas y Mark Goodfield. "Antimalarials". En Handbook of Systemic Drug Treatment in Dermatology, 61–66. 3a ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-7.
Texto completoMeunier, Bernard. "Towards Antimalarial Hybrid Drugs". En Polypharmacology in Drug Discovery, 423–39. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118098141.ch21.
Texto completoRosenthal, Philip J. "Antimalarial Drug Resistance: Clinical Perspectives". En Antimicrobial Drug Resistance, 1077–90. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-595-8_27.
Texto completoBiagini, Giancarlo A., Patrick G. Bray y Stephen A. Ward. "Mechanisms of Antimalarial Drug Resistance". En Antimicrobial Drug Resistance, 561–74. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-180-2_40.
Texto completoActas de conferencias sobre el tema "Antimalaria- Drug"
Kalogera, Eleftheria, Debarshi Roy, Ashwani Khurana, Susmita Mondal, Xiaoping He, Sean C. Dowdy y Viji Shridhar. "Abstract 261: Quinacrine in endometrial cancer: repurposing an old antimalarial drug". En Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-261.
Texto completoKapelle, Imanuel Berly Delvis, Shielda Natalia Joris, Natelda Rosaldiah Timisela, Esther Kembauw, Marthinus Johanes Saptenno y Fransisca Kissya. "Product diversification of katang-katang leaf (Ipomoea pescaprae) as an antimalarial drug". En THE 7TH INTERNATIONAL CONFERENCE ON BASIC SCIENCES 2021 (ICBS 2021). AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0113993.
Texto completoMegantara, Sandra, Jutti Levita y Slamet I. Surantaatmadja. "In Silico Study of Andrographolide as Protease Inhibitors for Antimalarial Drug Discovery". En 3rd International Conference on Computation for Science and Technology (ICCST-3). Paris, France: Atlantis Press, 2015. http://dx.doi.org/10.2991/iccst-15.2015.8.
Texto completoRodriguez Henriquez, P., F. J. Reyes-Muciño y L. M. Amezcua-Guerra. "AB0393 Electrocardiographic disturbances in patients with rheumatoid arthritis using antimalarial drugs". En Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5668.
Texto completoJulianto, Tatang Shabur, Rizki Ariadi Tama y Amri Setyawati. "Synthesis of aryl amino alcohol derivate from turpentine oil as a potential antimalarial drug". En 3RD INTERNATIONAL CONFERENCE ON CHEMISTRY, CHEMICAL PROCESS AND ENGINEERING (IC3PE). AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0062834.
Texto completoAbbas, Jamilah, Nina Artanti, Andini Sundowo, Indah Dwiatmi Dewijanti, Muhammad Hanafi, Lisa y Din Syafrudin. "Targetting the hemozoin synthesis pathway for antimalarial drug and detected by TEM (Transmission electron microscope)". En PROCEEDINGS OF THE 3RD INTERNATIONAL SYMPOSIUM ON APPLIED CHEMISTRY 2017. Author(s), 2017. http://dx.doi.org/10.1063/1.5011930.
Texto completoRiesco Barcena, C., S. Leal Rodríguez, ME Acosta de la Vega, E. Grau García, C. Pávez Perales, AV Huaylla Quispe, M. De la Rubia et al. "PO.8.175 Antimalarial drugs and electrocardiographic alterations in patients with systemic lupus erythematosus". En 13th European Lupus Meeting, Stockholm (October 5–8, 2022). Lupus Foundation of America, 2022. http://dx.doi.org/10.1136/lupus-2022-elm2022.194.
Texto completoFasinu, Pius. "The metabolism of the 8-aminoquinolines in relation to hemolytic toxicity: exploring current understanding for future antimalarial drug discovery". En ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.140510.
Texto completoTisnerat, Camille, Jérémy Schneider, René Pemha, Céline Damiani, Patrice Agnamey, Catherine Mullié, Anne Totet, Alexandra Dassonville-Klimpt y Pascal Sonnet. "Synthesis and biological evaluation of new enantiopure 4-aminoalcohol-quinoline and -fluorene hybrids as antimalarial drugs". En 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07397.
Texto completo"Virtual Screening the Interaction of Various Compound from Indonesian Plants with the HGXPRT Enzyme to Find a Novel Antimalarial Drug". En The 3rd International Conference on Life Sciences and Biotechnology. Galaxy Science, 2021. http://dx.doi.org/10.11594/nstp.2021.0805.
Texto completoInformes sobre el tema "Antimalaria- Drug"
Dhawan, B. N. Evaluation of New Antimalarials. Development of New Antimalarial Drugs. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 1991. http://dx.doi.org/10.21236/ada242409.
Texto completoTesfaselassie, Elias. Antimalarial Drug Discovery using Triazoles to Overcome Chloroquine Resistance. Portland State University Library, enero de 2000. http://dx.doi.org/10.15760/etd.2503.
Texto completoHodson Shirley, Cheryl. The Antimalarial Activity of PL74: A Pyridine-Based Drug Candidate. Portland State University Library, enero de 2000. http://dx.doi.org/10.15760/etd.1820.
Texto completoBasagoitia, Andrea. Do home- or community-based programmes for treating malaria improve health outcomes? SUPPORT, 2017. http://dx.doi.org/10.30846/170313.
Texto completoAvery, Mitchell A. Directed Synthesis of New Antimalarials Using Computer Aided Drug Design. Fort Belvoir, VA: Defense Technical Information Center, octubre de 1995. http://dx.doi.org/10.21236/ada303867.
Texto completoAvery, Mitchell A. Directed Synthesis of New Antimalarials using Computer Aided Drug Design. Fort Belvoir, VA: Defense Technical Information Center, octubre de 1995. http://dx.doi.org/10.21236/ada304919.
Texto completoParshikov, I. A., C. E. Hernandes-Luna y E. I. Zaraisky. Microbial transformation of the antimalarial and anticancer drug artemisinin by white-rot basidiomycetes. Global Science Publications, 2018. http://dx.doi.org/10.18411/0972-3005_n4.
Texto completoAvery, Mitchell A. Drug Development of the Antimalarial Agent Artemisinin: Total Synthesis, Analog Synthesis, and Structure-Activity Relationship Studies. Fort Belvoir, VA: Defense Technical Information Center, agosto de 1990. http://dx.doi.org/10.21236/adb152141.
Texto completoLiebman, Katherine. New 4-Aminoquinoline Compounds to Reverse Drug Resistance in P. falciparum Malaria, and a Survey of Early European Antimalarial Treatments. Portland State University Library, enero de 2000. http://dx.doi.org/10.15760/etd.2112.
Texto completo